(Q33714127)

28 July 2017

1 reference

title

Ropinirole and pramipexole, the new agonists (English)

1 reference

28 July 2017

Hobson DE

1

1 reference

PubMed ID

10451757

28 July 2017

Pourcher E

series ordinal

2

1 reference

PubMed ID

10451757

28 July 2017

Martin WR

series ordinal

3

1 reference

28 July 2017

1 August 1999

1 reference

Canadian Journal of Neurological Sciences

28 July 2017

1 reference

28 July 2017

26 Suppl 2

1 reference

28 July 2017

S2

1 reference

28 June 2019

page(s)

S27-33

1 reference

Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture.

28 July 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Levodopa-induced dyskinesia: review, observations, and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Drug treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Levodopa: is toxicity a myth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

Pharmacologic profile of ropinirole: a nonergoline dopamine agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Neurotoxicity of levodopa on catecholamine-rich neurons

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Pharmacokinetic data for ropinirole

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

A functional test identifies dopamine agonists selective for D3 versus D2 receptors.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Pramipexole in patients with early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Attempts to obtain neuroprotection in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Pergolide in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Continuous and intermittent levodopa differentially affect basal ganglia function

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100000068

7 January 2021

10.1017/S0317167100000068

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10451757